Document is current
Any future updates will be listed below
-
Authors
Rodin, William
Szeponik, Louis
Rangelova, Tsvetanka
Tamiru Kebede, Firaol
Österlund, Tobias
Sundström, Patrik
Hogg, Stephen
Wettergren, Yvonne
Cosma, Antonio
Ståhlberg, Anders
Bexe Lindskog, Elinor https://orcid.org/0000-0003-1466-1486
Quiding Järbrink, Marianne https://orcid.org/0000-0002-1978-8091
-
Funding
Funding for this research was provided by:
Stiftelsen Assar Gabrielssons Fond
Vetenskapsrådet (2021-01008, 55X-13428)
Cancerfonden (22-2080, 130593)
Swedish gouvernment (965065, 144381)
Sjöbergstiftelsen
Västra Götalandsregionen
University of Gothenburg
- License Information
-
More Information
Article History
Received: 16 January 2024
Accepted: 11 June 2024
First Online: 2 July 2024
Declarations
:
: AS declares stock ownership and is a board member in Tulebovaasta, Iscaff Pharma, and SiMSen Diagnostics. AS is co-inventor of the SiMSen-Seq technology that is patent protected (US Serial No.:15/552,618). MQJ has received consultancy fees from Biomunex Pharmaceuticals.
: This study was performed according to the Declaration of Helsinki and approved by the Regional Board of Ethics in Medical Research in west Sweden (249–15, approved 06/03/2015).
: All patients gave a written informed consent before participation in the study.
